Who
Richard Mulligan
Director
Company insider
Files Form 4 as: Head of SanaX, Sana Biotechnology; Director, International Flavors & Fragrances; Director, Bausch Health Companies; Director, Biogen; Director, Enzon Pharmaceuticals; Director, Imclone Systems.
In numbers
- Trades disclosed
- 69
- Buys
- 0
- Sells
- 5
- Bought
- $0
- Sold
- $12.2M
- Companies
- 6
- Companies where not an officer
- 5
- First trade
- 20 Sep 2006
- Last trade
- 4 Jun 2026
- Last filed
- 5 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 4 Jun 2026filed 5 Jun 2026 | SANA Sana Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —90,000 at $0.00 | filing |
| 4 Jun 2026filed 5 Jun 2026 | SANA Sana Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —90,000 at $0.00 | filing |
| 1 May 2026filed 4 May 2026 | IFF International Flavors & FragrancesChemicals | SEC FORM 4 Code M | —1,712 at $0.00 | filing |
| 1 May 2026filed 4 May 2026 | IFF International Flavors & Fragrancesoption or derivative · Chemicals | SEC FORM 4 Code M | $121K1,712 at $70.81 | filing |
| 1 May 2026filed 4 May 2026 | IFF International Flavors & Fragrancesoption or derivative · Chemicals | SEC FORM 4 Code M | $121K1,712 at $70.81 | filing |
| 1 May 2026filed 4 May 2026 | IFF International Flavors & FragrancesChemicals | SEC FORM 4 Code M | —1,712 at $0.00 | filing |
| 29 Apr 2026filed 30 Apr 2026 | IFF International Flavors & Fragrancesoption or derivative · Chemicals | SEC FORM 4 Code A | —2,903 at $0.00 | filing |
| 29 Apr 2026filed 30 Apr 2026 | IFF International Flavors & Fragrancesoption or derivative · Chemicals | SEC FORM 4 Code A | —2,903 at $0.00 | filing |
| 3 Nov 2025filed 4 Nov 2025 | IFF International Flavors & Fragrancesoption or derivative · Chemicals | SEC FORM 4 Code A | —1,712 at $0.00 | filing |
| 5 Jun 2025filed 9 Jun 2025 | SANA Sana Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —80,000 at $0.00 | filing |
| 16 May 2025filed 20 May 2025 | BHC Bausch Health CompaniesPharmaceuticals | SEC FORM 4 Code A | —54,347 at $0.00 | filing |
| 25 Sep 2024filed 26 Sep 2024 | SANA Sana BiotechnologyBiotechnology | SEC FORM 4 Sold | $584K150,000 at $3.89 | filing |
| 24 Sep 2024filed 26 Sep 2024 | SANA Sana BiotechnologyBiotechnology | SEC FORM 4 Sold | $612K150,000 at $4.08 | filing |
| 6 Jun 2024filed 15 Jul 2024 | SANA Sana Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —65,000 at $0.00 | filing |
| 6 Jun 2024filed 7 Jun 2024 | SANA Sana Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —54,278 at $0.00 | filing |
| 17 May 2024filed 20 May 2024 | BHC Bausch Health CompaniesPharmaceuticals | SEC FORM 4 Code A | —35,360 at $0.00 | filing |
| 19 May 2023filed 19 May 2023 | BHC Bausch Health CompaniesPharmaceuticals | SEC FORM 4 Code A | —29,205 at $0.00 | filing |
| 2 Mar 2023filed 3 Mar 2023 | SANA Sana Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 24 Jun 2022filed 28 Jun 2022 | BHC Bausch Health CompaniesPharmaceuticals | SEC FORM 4 Code A | —34,387 at $0.00 | filing |
| 15 Jun 2022filed 17 Jun 2022 | BIIB BiogenBiotechnology | SEC FORM 4 Code A | —1,370 at $0.00 | filing |
News
Biogen (NASDAQ:BIIB) Hits New 52-Week High Following Analyst UpgradeBIIB · dailypolitical.com · 14 Oct 2026Biogen (BIIB) vs Amgen (AMGN) and Gilead (GILD): Which Big Pharma Stock is a Better Buy?BIIB · insidermonkey.com · 13 Oct 2026Biogen (NASDAQ:BIIB) Stock Price Target Cut by Royal Bank Of CanadaBIIB · themarketsdaily.com · 8 Oct 2026
0 headlines in the last 90 days name Richard Mulligan; 3 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.